Sun Pharma Advanced Research Company (SPARC) announced positive top-line results from pivotal phase 3 clinical trial of PDP-716 for the treatment of ocular hypertension.
SPARC reported positive top-line results from its Phase 3 trial (CLR 16 33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of open angle glaucoma or ocular hypertension.
PDP-716 is a novel, once daily, ophthalmic suspension of Brimonidine Tartrate 0.35%. PDP-716 is developed using SPARC s proprietary TearAct technology.
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day. We are very pleased by these results for PDP-716. Once daily dosing of PDP-716 can significantly reduce the dosing frequency compared to currently marketed formulation and can have positive impact on quality of life for patients with Glaucoma. said Anil Raghavan, CEO of SPARC.
Sun Pharma Advanced issues warrants worth Rs 1,200 cr to promoter, marquee investors like Jhujhunwala
SECTIONS
Sun Pharma Advanced issues warrants worth Rs 1,200 cr to promoter, marquee investors like JhujhunwalaBy
Share
Synopsis
The company will issue 6.74 lakh warrants that can be converted to one equity share of the company over the next 18 months, a stock exchange filing by the company showed.
ThinkStock Photos
The warrants are being issued at Rs 178 per share, which translated to a 26 per cent discount to the stock’s secondary market closing price of Rs 241
Related
NSE
MUMBAI:
Sun Pharma Advanced Research today said that it has issued warrants worth Rs 1,200.96 crore to its promoter Dilip Shanghvi and other marquee investors like Rekha Jhunjhunwala (wife of Rakesh Jhunjhunwala) and Ashish Maheshwari.
SPARC to raise ₹1,201 cr from promoter, 34 others
May 12, 2021
The board of director of Sun Pharma Advanced Research Company Ltd on Wednesday approved a proposal to raise up to ₹1,200.97 crore to Dilip Shantilal Shanghvi, Promoter of the company and to 34 other non-promoter group persons, including Rekha Jhunjhunwala, Authum Investment, University of Notre Dame DU Lac, Cohesion Investment (Cayman), Ashish Maheshwari and Abakkus Growth Fund, by way of preferential issue.
The board has approved to issue up to 6.75 crore warrants each convertible into, or exchangeable for, one equity share within the period of 18 months at ₹178 each.
Shares of SPARC jumped 6.14 per cent at ₹239.55 on the BSE.
Brand Opus India announces winners of Business Icon Awards 2021 ANI | Updated: Feb 17, 2021 13:17 IST
Bangalore (Karnataka) [India], February 17 (ANI/NewsVoir): Business Icon Awards - 2021 has been organised by Brand Opus India to recognise the various organisations & companies, entrepreneurs & service providers for their outstanding performance and achievements in their respective fields.
These Awards are going to be a small token of appreciation for the individuals who are pushing the boundaries to make an honorable future of this society. It will motivate other great minds to strive towards aphelion.
The awards are an ode to the indomitable spirit of the winners, conceived and initiated by Brand Opus India - Best Brand Management Company in India.
CEAT a better bet than Balkrishna Inds
Right levels to buy Vodafone - Rs 14 in near term
On Buy Now Sell Now we caught up with Kunal Bothra, kunalbothra.co.in and Ashish Maheshwari, Director, Blue Ocean Strategic Advisors to get all your stock-related queries answered as the markets scale to new high.
Query 1
Viewer Name: Pankaj Gupta
I Am Holding 4,000 Shares Of DHFL. Is It Being Delisted Or Merged With Piramal Enterprise? Please Share Your Outlook.
Kunal’s View: I would focus on the Piramal Chart over DHFL. Piramal Enterprise has been underperforming since last 6-7 months vs other NBFCs. Charts are indicating that the stock will see a new trend emerging very soon. Buy for a near-term target of Rs. 2,200.